Related Experiment Video
Updated: May 22, 2026
Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
Published on: May 8, 2016
Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome
Makoto Inoue1, Kristi L Williams, Timothy Oliver
1Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA.
Abstract:
Interferon-β (IFN-β) is widely used to treat multiple sclerosis (MS), and its efficacy was demonstrated in the setting of experimental autoimmune encephalomyelitis (EAE), an animal model of MS; however, IFN-β is not effective in treating all cases of MS. Here, we demonstrate that signaling by IFNAR (the shared receptor for IFN-α and IFN-β) on macrophages inhibits activation of Rac1 and the generation of reactive oxygen species (ROS) through suppressor of cytokine signaling 1 (SOCS1). The inhibition of Rac1 activation and ROS generation suppressed the activity of the Nod-like receptor (NLR) family, pyrin domain-containing 3 (NLRP3) inflammasome, which resulted in attenuated EAE pathogenicity. We further found that two subsets of EAE could be defined on the basis of their dependency on the NLRP3 inflammasome and that IFN-β was not an effective therapy when EAE was induced in an NLRP3 inflammasome-independent fashion. Thus, our study demonstrates a previously uncharacterized signaling pathway that is involved in the suppression of EAE by IFN-β and characterizes NLRP3-independent EAE, which cannot be treated with IFN-β.
Insights
Interferon-beta (IFN-β) treats multiple sclerosis (MS) by inhibiting the NLRP3 inflammasome via IFNAR signaling on macrophages. However, some MS cases are NLRP3-independent and do not respond to IFN-β therapy.
Area of Science:
- Immunology
- Neuroscience
- Cellular Biology
Background:
- Interferon-beta (IFN-β) is a standard treatment for multiple sclerosis (MS).
- Its efficacy in the EAE model suggests a therapeutic role, but it fails in some MS patients.
- The underlying mechanisms of IFN-β action and treatment resistance are not fully understood.
Purpose of the Study:
- To elucidate the signaling pathway through which IFN-β suppresses experimental autoimmune encephalomyelitis (EAE).
- To identify mechanisms of resistance to IFN-β therapy in EAE.
- To characterize distinct subsets of EAE based on inflammasome dependency.
Main Methods:
- Investigated IFNAR signaling on macrophages in EAE.
- Assessed the role of Rac1, reactive oxygen species (ROS), and the NLRP3 inflammasome.
- Utilized an EAE model to evaluate IFN-β efficacy in NLRP3-dependent and -independent disease.
Main Results:
- IFNAR signaling on macrophages inhibits Rac1 activation and ROS generation via SOCS1.
- This inhibition suppresses NLRP3 inflammasome activity, reducing EAE pathogenicity.
- Identified two EAE subsets: one dependent on NLRP3 inflammasome, the other independent.
- IFN-β was ineffective in NLRP3-independent EAE.
Conclusions:
- Discovered a novel IFN-β signaling pathway involving SOCS1, Rac1, ROS, and the NLRP3 inflammasome in EAE suppression.
- Characterized a subset of EAE that is resistant to IFN-β due to NLRP3 inflammasome independence.
- These findings highlight the importance of inflammasome status in predicting IFN-β treatment response in MS.
